NACE 46.45 in FR. Official registry identity, company-size evidence and a rounded indicative valuation range on one indexed company profile.
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on official company-size informationCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
You have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
HENNEDROG's indicative range combines official company-size information with sector multiples. It publishes no midpoint, asking price, offer, or recommendation and only becomes company-specific after refinement with owner or advisor data.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
HENNEDROG is a business in NACE sector 46.45 based in France. The company was founded in 1973, incorporated as a 5710.
HENNEDROG is listed in French National Business Register (RNE/INPI) under registry number 073803785. The public employee band is 03, a useful triage field for banks, credit analysts, and M&A acquirers. This profile consolidates official annual accounts into one indexable company dossier.
Companies in this NACE 46.45 band file annual accounts with INPI.
HENNEDROG's public range combines official company-size information with sector multiples. It remains indicative and is not a midpoint, sale price, offer, or recommendation.
The most recent annual filing covers 2025 (period end 2025-06-30).
If you are researching HENNEDROG, this page combines its official registry profile and company-size evidence with a broad indicative range.
Public regulator-filed figures across 8 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202530 Jun 2025 | - | - | €4,578,790 | €3,476,251 | - |
| 202430 Jun 2024 | - | - | €3,995,173 | €3,080,245 | - |
| 202330 Jun 2023 | - | - | €3,393,270 | €2,681,626 | - |
| 202230 Jun 2022 | - | - | €3,061,377 | €2,325,279 | - |
| 202130 Jun 2021 | - | - | €3,587,140 | €3,008,123 | - |
| 201930 Jun 2019 | - | - | €3,032,626 | €2,273,403 | - |
| 201830 Jun 2018 | - | - | €3,169,983 | €2,432,029 | - |
| 201730 Jun 2017 | - | - | €3,003,409 | €2,141,786 | - |
HENNEDROG was founded in 1973 and is registered with French National Business Register (RNE/INPI), incorporated as a 5710.
HENNEDROG is registered under NACE 46.45: NACE 46.45. That places the business within the French cluster for this activity.
The most recently filed annual accounts cover fiscal year 2025 (period end 2025-06-30), publicly available via French National Business Register (RNE/INPI).
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for HENNEDROG may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
